China has engaged in more than a dozen countries to conduct end-stage testing of its COVID-19 experimental vaccines as it seeks to stay ahead of the curve in the foreign race to vaccinate the world’s population as a component of its charm offensive to gain goodwill.
Around the world, in many countries, including Peru, Argentina, Brazil, Bahrain, egypt, Pakistan, Turkey, Morocco, Saudi Arabia, Bangladesh, Indonesia and Russia, thousands of people have won experimental vaccine injections made through China’s 3 leading vaccine brands or will soon be, the Hong Kong-based South China Morning Post reported tuesday , with statements from the company, the government and the media.
For at least some of these countries, the approval of the final stages of clinical trials was seen as a means of ensuring early access to vaccines, as several rich countries have already purchased doses awaiting approval and a mechanism from the World Health Organization (WHO).
In recent weeks, the media has cited officials from Mexico, Bangladesh and Pakistan saying that trials are a way to approve vaccines in the future.
On 25 September, a Chinese fitness officer said WHO had supported the emergency use of experimental vaccines in China, clinical trials have not yet been completed.
Zheng Zhongwei, head of medical science progression at the National Health Commission, told the media that WHO had given its blessing to China for the use of vaccine emergencies by the end of June.
According to Zheng, the commission proposed the emergency use of vaccines in mid-June to other people in high-risk jobs, such as front-line fitness personnel, border personnel, and foreign personnel. The vaccines were still expected to complete phase 3 of the clinical trials. however, the State Council approved the proposal on June 24.
“After the approval, on 29 June, we had a communication meeting with the relevant representatives of WHO’s workplace in China, and we received understanding from WHO,” Zheng said, referring to the Post.
He said the approval strictly complied with Chinese vaccines and pharmaceuticals and used WHO criteria as a guide, adding that there were no serious adverse occasions due to injections.
WHO has been the subject of strong criticism from US President Donald Trump, who accused him of being a puppet of China for not acting in time to prevent the spread of COVID-19 when it erupted in the Chinese city of Wuhan in December last year. Trump also withdrew the United States from WHO.
In his address to the United Nations General Assembly on 23 September, Trump also attacked WHO because it is “virtually controlled by China. “
Last week, President Yang Xiaoming of China’s National Biotec Group, who had been granted permission to begin Phase 3 trials for his coronavirus vaccine applicants in the United Arab Emirates, said another 350,000 people had been injected with experimental vaccines under the program.
Yang Sheng, deputy director of the National Medical Products Administration’s drug recorder, said 4 COVID-19 vaccines developed in China had begun the last level of human trials after obtaining approval from foreign authorities.
China has focused on the progression of five types of vaccines, and the focus has at least one ongoing clinical trial. A total of 11 candidate vaccines are at other testing stages, Yang said, as cited through China Daily, a public body.
Listen to the newest songs in JioSaavn. com
Zheng said China’s annual capacity to manufacture COVID-19 vaccines is expected to succeed at 610 million doses this year and one billion doses until 2021, and did not give major points on how doses will be distributed.
Faced with global adversity in the face of the great spread of coronavirus, China plans to conduct a diplomatic offensive by providing its vaccines, especially to several small countries at a cost price.
Follow the coronavirus pandemic in India and get the latest COVID-19 news from around the world in ndtv. com/coronavirus
Watch the live:
Follow us:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Advertising. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .